Welcome to the Technology Networks Research Store, leading strategic market analysis for the Biotech and Healthcare sector from the most trusted sources in the world. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (32)

5,000 - 9,999 (59)

10,000 - 49,999 (121)

50,000+ (45)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (21)

500 - 999 (13)

1,000 - 1,999 (48)

2,000+ (201)

Top stories

NextGen and InterSystems partner with MHC to enable health information exchange

NextGen Healthcare Information Systems, LLC. and InterSystems, a developer of software for connected healthcare, have announced that the two companies have demonstrated cross-vendor interoperability to enable on-demand, bi-directional data exchange with Missouri Health Connection, or MHC...more >>

Agilent upgrades SurePrint miRNA Microarrays

Agilent Technologies, Inc., a provider of electronic and bio-analytical measurement equipment, has upgraded its SurePrint miRNA Microarrays to include targets from the new public miRNA miRBase database...more >>

Carl Zeiss introduces cataract surgery products

Carl Zeiss Meditec AG, a provider of medical technology solutions, has announced the introduction of the ZEISS Cataract Suite markerless and a nonexclusive commercial collaboration under which Abbott will distribute the ZEISS portfolio of Cataract Surgery Products in the US...more >>

Cerus submits Compassionate Use IDE for Ebola convalescent plasma treatment

Cerus Corporation, a biomedical products company, has submitted a clinical protocol to the FDA to make the INTERCEPT Blood System for plasma available under a Compassionate Use Investigational Device Exemption, or IDE, for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy...more >>